CSL (ASX: CSL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
CSL Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
CSL (ASX: CSL)
Latest News
Share Market News
5 top ASX ETFs to buy and hold for 5 years+
Growth Shares
3 proven ASX compounders that could double your money over time
How to invest
How to make your first $10,000 in the ASX share market
Share Market News
Top 10 most-traded Australian shares last week
Broker Notes
Morgans names 3 ASX 200 shares to buy in November
Share Market News
CSL flags influenza growth at 2025 Capital Markets Day
Blue Chip Shares
3 high-quality ASX 200 blue chip shares to buy and hold for 10 years
Broker Notes
Expert sees 34% upside potential for CSL shares despite ongoing challenges
Broker Notes
Top brokers name 3 ASX shares to buy next week
Healthcare Shares
Here's how Morgans rates the 3 biggest ASX 200 healthcare shares
Healthcare Shares
Can CSL shares bounce back? 3 experts share their views after brutal 36% sell-off
Broker Notes
Top brokers name 3 ASX shares to buy today
Frequently Asked Questions
-
CSL was listed on the ASX in June 1994.
-
CSL has paid twice yearly dividends every year since late 1997, a little over three years after the company’s initial listing on the ASX. Up until early 2005, CSL’s dividends were all fully franked. Since then, franking credits have been intermittent.
Since 2021 CSL has paid an unfranked interim dividend in April and a 10% franked final dividend in September/October.
-
CSL has a dividend reinvestment plan, however, it has not been active since 2004. Instead, CSL periodically executes share buybacks as a way of delivering additional returns for shareholders.
-
CSL originally floated in 1994 at $2.30 per share. However, taking into account share buybacks, the adjusted entry price is equivalent to around 76 cents.
CSL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About CSL
CSL Limited (ASX: CSL) is an Australian-based global biotechnology company that develops and delivers biotherapies and vaccines to protect public health and help people with life-threatening medical conditions live full lives.
CSL has been in operation for more than a century and was listed on the ASX in 1994. Today, the blue-chip healthcare company is one of the largest on the ASX.
CSL’s operational businesses include CSL Behring, CSL Seqirus and CSL Vifor. Its Plasma business operates one of the largest plasma collection networks in the world. CSL is recognised for its global leadership in three main areas: rare and serious diseases, vaccine development, and iron deficiency and nephrology (kidney research).
The company operates in over 40 countries, predominantly Australia, the United States, Germany, the United Kingdom, and Switzerland.
